Hydrophenanthrene Nucleus Patents (Class 562/403)
  • Patent number: 9259404
    Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: February 16, 2016
    Assignee: Nestec S.A.
    Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Jane Durga, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi, Pierre Magistretti, Evelyne Ruchti, Sylvain Lengacher, Igor Allaman
  • Patent number: 8920830
    Abstract: The present invention relates to wound dressings having a wound contacting layer that contains a wound healing composition and which is adapted to maintain a temperature different from ambient, for example achieve and maintain a heat-absorbing effect on the underlying tissues. The specific physico-chemical structure of the devices of the invention allows fluid containment and absorption of wound secretions while avoiding skin macerations.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 30, 2014
    Assignee: Laboratoire Medidom S.A.
    Inventor: Burkhard Mathies
  • Publication number: 20130203712
    Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: May 19, 2011
    Publication date: August 8, 2013
    Applicant: University of Iowa Research Foundation
    Inventors: Christopher M. Adams, Steven D. Kunkel
  • Patent number: 8466311
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 18, 2013
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A. Lipton, Takumi Satoh
  • Publication number: 20120296112
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Application
    Filed: September 19, 2011
    Publication date: November 22, 2012
    Inventors: Stuart A. Lipton, Takumi Satoh
  • Publication number: 20120251492
    Abstract: Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].
    Type: Application
    Filed: December 15, 2010
    Publication date: October 4, 2012
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Makoto Ishikawa, Shigeki Suzuki, Makoto Aoki, Nobuto Minowa, Kokichi Suzuki
  • Publication number: 20120142707
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 7, 2012
    Inventors: Alicia Regueiro-Ren, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell, Sing-Yuen Sit, Jie Chen
  • Publication number: 20120115951
    Abstract: A cardiac myocyte protective agent, comprising a compound represented by the formula (Ia) below, a pharmaceutically acceptable salt thereof, or a solvate thereof:
    Type: Application
    Filed: September 8, 2006
    Publication date: May 10, 2012
    Applicant: Eisai R & D Managment Co., Ltd
    Inventors: Masaharu Akao, Akinori Akaike, Toru Kita, Yasuki Kihara
  • Publication number: 20120101098
    Abstract: Compounds according to Formula (I) are described along with compositions containing the same and methods of use thereof for the treatment of viral infections.
    Type: Application
    Filed: May 10, 2010
    Publication date: April 26, 2012
    Inventors: Kuo-Hsiung Lee, Keduo Qian, Donglei Yu, Chin-Ho Chen, Li Huang, Ibrahim Danlami Bori
  • Patent number: 8022246
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: September 20, 2011
    Assignee: The Burnham Institute for Medical Research
    Inventors: Stuart Lipton, Takumi Satoh
  • Publication number: 20110190388
    Abstract: Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.
    Type: Application
    Filed: May 18, 2010
    Publication date: August 4, 2011
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Chun-Nan Lin, Huang-Yao Tu, A-Mei Huang, Bai-Luh Wei, Kim-Hong Gan, Tzyh-Chyuan Hour, Shyh-Chyun Yang, Yeong-Shiau Pu, Shen-Jeu Won
  • Publication number: 20110166038
    Abstract: High-throughput methods are provided for quantitatively measuring the modulation of heat shock protein (HSP) expression in a cell by exposing the cell to at least one stress and measuring cellular stress responses. High-throughput methods for identifying modulators (activators or inhibitors) of HSP or HSF expression in a cell by treating the cell with an agent, such as a compound or composition, exposing the cell to a stress, and measuring responses of the cell to the stress in the presence or absence of the agent are also provided. Devices useful in performing high-throughput methods of the invention, and modulators identified using such methods, are also provided.
    Type: Application
    Filed: June 3, 2009
    Publication date: July 7, 2011
    Inventors: Bin Zhang, Shi Chung Ng, Qingyan Au
  • Patent number: 7858824
    Abstract: The present invention relates to compounds of formula (IIIo): in which n is an integer from 1 to 5; Ao represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: December 28, 2010
    Assignee: sanofi-aventis
    Inventors: Marco Baroni, Bernard Bourrie, Rosanna Cardamone, Pierre Casellas
  • Patent number: 7612225
    Abstract: Disclosed herein are a novel crystal of a novel triterpene derivative, a method for producing the crystals, and a pharmaceutical preparation obtained by using the crystals.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: November 3, 2009
    Assignee: Shionogi & Co., Ltd.
    Inventor: Masataka Fumoto
  • Publication number: 20080145322
    Abstract: The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.
    Type: Application
    Filed: September 14, 2005
    Publication date: June 19, 2008
    Inventor: Gary R. Eldridge
  • Publication number: 20080064753
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Application
    Filed: July 14, 2006
    Publication date: March 13, 2008
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young Ger Suh
  • Publication number: 20070197646
    Abstract: Substituted taraxastanes useful for treating viral infections, are provided herein. Thus, in a first aspect, the invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, wherein the variables R1, R2, and X are defined herein. The compounds described herein are thought to act by inhibiting retroviral maturation, including maturation of encapsulated retroviruses viruses, such as the HIV viruses, HIV-1 and HIV-2. Pharmaceutical compositions comprising such compounds of Formula I are included herein. Methods of using such compounds to treat human patients infected with an HIV virus and reducing the mortality of AIDS are also provided herein.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 23, 2007
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Barton James BRADBURY, Mingjun Huang
  • Publication number: 20040192777
    Abstract: Two compounds namely ent-pimmarane 8(14),15-diene-19 oic acid (compound 1) and ent-pimmarane 7(8),9(11),15-diene-19 oic acid (compound 2) were isolated from Lavatera cachmeriania, these compounds, in vitro, significantly inhibited the growth of number of human cancer cell lines (CNS : SK-N-MC, Colon : HT-29, Lung : A-549 , Liver: Hep-2, Ovary: OVCAR-5, Prostate: PC-3) representing different organs.
    Type: Application
    Filed: March 28, 2003
    Publication date: September 30, 2004
    Applicants: COUNCIL OF SCIENTIFIC AND INDUSTRIAL, REGIONAL RESEARCH INSTITUTE OF UNANI MEDICINE (Central Council of Research in U.M. New Delhi)
    Inventors: Mohammad Yaseen Dar, Mohammad Yousuf, Mushtaq A. Qurishi, Anees A. Ansari, Shamshad Ahmad, Abdul Sami Shawl, Ajit Kumar Saxena, Gulam Nabi Qazi
  • Publication number: 20030232786
    Abstract: Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.
    Type: Application
    Filed: January 15, 2003
    Publication date: December 18, 2003
    Inventors: Tadashi Honda, Frank G. Favaloro, Gordon W. Gribble, Michael B. Sporn, Nanjoo Suh
  • Patent number: 6538149
    Abstract: Compounds of the formula where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: March 25, 2003
    Assignee: Allergan
    Inventors: Vidyasagar Vuligonda, Alan T. Johnson, Roshantha A. Chandraratna
  • Publication number: 20030050338
    Abstract: Novel compounds are disclosed that have the following chemical structures, and prodrug esters and acid-addition salts thereof, that are useful as Interleukin-1 and Tumor Necrosis Factor-&agr; modulators, and thus are useful in the treatment of various diseases.
    Type: Application
    Filed: March 27, 2002
    Publication date: March 13, 2003
    Inventors: Michael Palladino, Emmanuel A. Theodorakis
  • Patent number: 6399549
    Abstract: A cyclic compound comprising m units of the formula Ia. and n units of the formula (Ib) joined together to form a ring, wherein Y and y2 are divalent bridging groups which may be the same or different in each unit; Ro is H or (C1-C6) alkyl or is a metal or amnmonium cation; R5 is H or (C1-C60) alkyl or OH group; j is 1 or 2; R3 is hydrogen, a hydrocarbyl or a hetero-substituted hydrocarbyl group; each of R1, R2 and R4, which may be the same or different, is hydroxyl, hydrogen, hydrocarbyl or hetero-substituted hydrocarbyl, with the provisos that i) at least one of R1, R2, R4 is hydroxyl, and m +n is 4 to 20, m is 1-8 and n is at least 3, and ii) in formula Ia at least one OH group is in the meta or para position to the COORo group and/or at least one R5 group is OH.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: June 4, 2002
    Assignee: BP Oil International Limited
    Inventors: Spencer Edwin Taylor, Michael John Wilson
  • Patent number: 6344585
    Abstract: A tetrahydrofluorene, which is represented by the following formula (I) wherein R1 to R6 each independently represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R1 and R2 are combined together to represent ═O, ═N or ═S, R7 and R8 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group or a carboxyl group, is subjected to a hydrogen transfer reaction in the presence of a hydrogen acceptor and a catalyst, whereby a fluorene and a hydride of the hydrogen acceptor are formed at the same time.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: February 5, 2002
    Assignee: Adchemco Corporation
    Inventor: Hiroaki Mori
  • Patent number: 6180815
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Patent number: 6175034
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Patent number: 5380925
    Abstract: Novel cyclic amino acids which are useful in preparing biologically active peptides as well as a process for the preparation of D and L enantiomers of the cyclic amino acids are described where an N-protected derivative of the racemic cyclic amino acid is treated with (-)cinchonidine and the resulting salt resolved into the desired enantiomers, as well as derivatives thereof and valuable intermediates used in the process.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: January 10, 1995
    Assignee: Warner-Lambert Company
    Inventors: Vladimir Beylin, Huai G. Chen, Om P. Goel, Mark E. Marlatt, John G. Topliss
  • Patent number: 5164527
    Abstract: Acylation or sulphonylation of aromatic compounds, one of which is selected from aromatic carboxylic and sulphonic acids and esters and anhydrides thereof, using an aluminosilicate catalyst having acidic sites.
    Type: Grant
    Filed: April 3, 1991
    Date of Patent: November 17, 1992
    Assignee: Imperial Chemical Industries PLC
    Inventor: Alan B. Newton
  • Patent number: 4963585
    Abstract: The invention relates to a compound of antimicrobial activity of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkanoyl,R.sup.2 is hydrogen or ##STR2## in which R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen or lower alkanoyl,R.sup.3 is carboxy or a protected carboxy, and pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 14, 1989
    Date of Patent: October 16, 1990
    Assignee: Fujisawa Pharmaceutical Company, Ltd.
    Inventors: Masanori Okamoto, Eisaku Tsujii, Tsutomu Kaizu, Hiroshi Hatanaka, Masakuni Okuhara, Kozo Sawada, Hirokazu Tanaka
  • Patent number: 4874891
    Abstract: Compounds of the formula: ##STR1## and the pharmaceutically acceptable esters thereof, wherein rings A and B are selected from the group consisting of ##STR2## wherein x represents an aromatic ring, or the presence or absence of 0, 1, or 2 conjugated or unconjugated .pi. bond(s), andwherein x represents the presence or absence of 0, 1, or 2 conjugated or unconjugated .pi. bond(s), andwherein a non-aromatic .pi. bond, if present, may optionally be converted to an epoxide;and wherein the dotted line represents the presence or absence of a .pi. bond,and wherein:R.sup.1 is H, acyl(1-6), or alkyl(1-6);R.sup.2 is H, alkyl(1.varies.6), 2-propynyl, or allenyl;R.sup.3 and R.sup.4 is each independently H or OR.sup.5, wherein R.sup.5 is H, acyl(1-6), or alkyl(1-6); andwherein R.sub.1 and R.sub.2 is each independently H, alkyl(1-6) or is --C.tbd.CR.sub.3, --CH.dbd.CHR.sub.3, or --CH.dbd.C.dbd.CHR.sub.3, wherein R.sub.3 is selected from the group consisting of H, halo, CF.sub.
    Type: Grant
    Filed: May 1, 1986
    Date of Patent: October 17, 1989
    Assignee: Washington University
    Inventors: Douglas F. Covey, Ricahrd J. Auchus
  • Patent number: 4585576
    Abstract: What is described is an improved opto-electronic component and display which uses novel liquid crystal nematic substances for the control of the light transmission and for the display of numbers symbols and images. The novel nematic liquid crystal substances herein, which exhibit high clearing temperatures, low working temperatures and rapid switching times, are 7-alkyl-perhydrophenanthren-2-carboxylic acids and esters thereof.
    Type: Grant
    Filed: April 23, 1984
    Date of Patent: April 29, 1986
    Assignee: VEB Werk fur Fernsehelektronik im VEB Kombinat Mikroelektronik
    Inventors: Dietrich Demus, Horst Zaschke, Sabine Richter, Hans-Joachim Deutscher, Adelbert Wiegeleben
  • Patent number: 4361578
    Abstract: The invention is directed to 3-oxo-D-homosteroids and derivatives thereof which are useful as antiantigens.
    Type: Grant
    Filed: November 16, 1981
    Date of Patent: November 30, 1982
    Inventors: Leo Alig, Andor Furst, Peter Keller, Marcel Muller, Ulrich Kerb, Rudolf Wiechert
  • Patent number: 4260798
    Abstract: The present invention provides novel 13,14-dihydro-inter-3,7-inter-m-phenylene-4,5,6-trinor-3-oxa-9-deoxy-9-met hylene-19-oxo-PGF.sub.1 compounds, which are useful for a variety of pharmacological purposes, e.g., antiasthmatic indications.
    Type: Grant
    Filed: March 20, 1980
    Date of Patent: April 7, 1981
    Assignee: The Upjohn Company
    Inventor: John C. Sih
  • Patent number: 4173648
    Abstract: 3.beta.-Hydroxy-18.beta.-olean-9-en-30-oic acids having anti-ulcer activity of the formula ##STR1## compositions containing the same and process for their preparation.
    Type: Grant
    Filed: March 13, 1978
    Date of Patent: November 6, 1979
    Assignee: I.S.F. SpA
    Inventors: Giorgio Pifferi, Achille Umani-Ronchi, Carlo Farina, Afro Gamba
  • Patent number: 4147777
    Abstract: Pharmaceutically active compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, each represents a hydrogen atom or a substituted or unsubstituted aliphatic or aromatic mono- or poly-carboxylic acid acyl radical and R.sub.5 represents a glycosyl group, are provided together with processes for their production and pharmaceutical compositions containing them. These compounds possess valuable cicatrizing and anti-inflammatory properties.
    Type: Grant
    Filed: March 17, 1977
    Date of Patent: April 3, 1979
    Assignee: Inverni Della Beffa S.p.A.
    Inventor: Giuseppe Mustich